Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors

Luye Pharma Group

Status and phase: Unknown; Phase 3

Conditions: Bone Metastases From Solid Tumors

Treatments: Drug: Xgeva®; Drug: LY01011

Study type: Interventional

Funder types: Industry

Identifiers

NCT04859569

LY01011/CT-CHN-303

Details and patient eligibility

About

This is a multicenter，randomized, double-blind, active-controlled, parallel-group study comparing efficacy and safety of LY01011 (recombinant anti-RANKL human monoclonal antibody injection) and Xgeva® in patients with bone metastases from solid tumors.

Full description

The primary objective is to evaluate the similarity of clinical efficacy between LY01011 and Xgeva® in patients with bone metastases from solid tumors.

The secondary objective is to evaluate the similarity of clinical safety and immunogenicity between LY01011 and Xgeva® in patients with bone metastases from solid tumors.

Each subject will participate in the study for 53 weeks. Treatments are administered on day 1 and Q4W thereafter through week 49. All patients are instructed to take 500 mg calcium and 400 IU vitamin D daily.

Enrollment: 850 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• The subject or his/her guardian and/or impartial witness voluntarily signed the written informed consent form（ICF）.
• Aged 18 to 80 Years old (Female or male subjects to the date of signing the informed consent form).
• Subjects with solid tumor confirmed by histological or cytological examination. At least one documented bone metastasis confirmed by computed tomography[CT], magnetic resonance imaging[MRI]) or pathology (bone biopsy).
• Eastern Cooperative Oncology Group（ECOG）performance status≤2.
• Adequate organ function at baseline.

Exclusion criteria

• Prior treatment with denosumab or other RANKL-targeted therapeutic drugs.
• Subjects who previously received any bone-modifying agents (including intravenous or oral bisphosphonates, etc.) for advanced tumor disease.
• Orthopedic surgery or bone-related radiation therapy within 1 month prior to first dose. Bone radioisotope therapy within 6 months prior to first dose, or planned radiation therapy or surgery for bone during the study.
• Past or ongoing osteomyelitis or osteonecrosis of the jaws （ONJ）, an active dental or jaw condition requiring oral surgery, non-healed dental or oral surgery, or any planned invasive dental procedure during the study period.
• Primary central nervous system malignancy. Subjects with central nervous system metastases who have failed local therapy. Subjects with asymptomatic brain metastases or clinically stable brain metastases who do not require steroids and other therapy for brain metastases for ≥ 28 days may be enrolled.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

850 participants in 2 patient groups

LY01011

Experimental group

Description:

Subcutaneous injection of LY01011 120 mg (1.7ml) every 4 weeks for a maximum of 13 consecutive doses up to week 49.

Treatment:

Drug: LY01011

Xgeva®+LY01011

Active Comparator group

Description:

After subcutaneous injection of Xgeva® 120 mg (1.7ml) every 4 weeks 3 times, patients of Xgeva® group continue to receive LY01011 120 mg (1.7ml) every 4 weeks for ten doses consecutively.

Treatment:

Drug: Xgeva®

Drug: LY01011